TERMIS 2021 | Clinical translation of regenerative nanoclays

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, provides an overview of barriers to developing regenerative nanoclays for the clinic. Refining the manufacturing process so that the final product adheres to good manufacturing process (GMP) standards and is clinical-grade is important. As the nanoclay additionally contains bone morphogenetic protein 2 (BMP-2), classification of the product may present challenges to regulatory authorities, and varying regulatory requirements across different countries will also present potential barriers. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).